Why weight loss can plateau on a GLP-1

A slower scale is common in chronic weight management

GLP-1 medicines used for weight management, including semaglutide and tirzepatide products, produce the fastest average loss in the first months of the large trials, then the curve flattens. That shape is how body-weight regulation works, not proof of failure. NIDDK describes prescription obesity medicines as adjuncts to diet and activity, used over the long term for many people, not as a short course that should produce a straight line down.

This article is educational troubleshooting, not a protocol to raise your own dose. Trial averages also hide people who lose little. Those non-response questions have their own pages for semaglutide and tirzepatide.

What SURMOUNT and STEP curves actually show

STEP 1 reported a mean weight change of about 14.9% with semaglutide 2.4 mg versus 2.4% with placebo at 68 weeks, with loss accumulating over the year rather than only in month one. SURMOUNT-1 reported mean losses of about 15% to 21% at 72 weeks depending on tirzepatide dose. Those headline percentages are end-of-trial means, not weekly guarantees.

A 2025 Clinical Obesity analysis of SURMOUNT-1 and SURMOUNT-4 defined a plateau as less than 5% weight change over a 12-week window and all later 12-week windows, among people who had already lost at least 5%. Most of those participants had met that plateau definition by week 72. Higher tirzepatide doses and younger age were linked to a later plateau. The analysis cannot tell a specific reader when their line will flatten.

False plateaus: water, stool, muscle, and measurement

Constipation, a labeled GLP-1 effect, can add several pounds of stool and fluid. High-sodium meals, menstrual cycle phase, and starting resistance training can do the same. Weighing at different times of day creates fake stalls. A clinician may ask for a two-to-four-week trend rather than a single morning.

If GI side effects have eased, intake sometimes rises without the person noticing, because restaurant portions feel "fine" again. That is not moral failure. It is appetite biology plus environment. Educational diet and exercise pages can prepare questions for a visit. They are not calorie prescriptions from this site.

Dose, adherence, and tolerability

Many people are still on a titration dose when they first worry about a stall. Labels for Wegovy and Zepbound use stepwise increases. Staying at a starter dose because of nausea is a safety choice, not a secret extra-strength protocol. Missed weekly doses, delayed shipments, or injecting a device incorrectly can also flatten the curve.

Maximum labeled dose is not a goal for its own sake. Side effects such as vomiting raise kidney-injury risk. A plateau with good metabolic labs and better mobility can be a win. A plateau with rising glucose, uncontrolled blood pressure, or no loss after a full trial of a tolerated maintenance dose is a reason to reassess the whole plan with a clinician.

When a stall needs a clinician sooner

Call sooner if weight is rising rapidly, if new medicines (steroids, some psychiatric drugs, insulin) were added, if fatigue and cold intolerance suggest thyroid disease, or if pregnancy is possible. Rapid regain with severe GI symptoms also needs a look, because dehydration can confuse the scale.

Do not add a second GLP-1, borrow someone else's pen, or skip blood-pressure medicines to "reset" the scale. Those shortcuts create labeled safety problems. If the question is whether to stop, that is a separate, planned conversation. Rebound after withdrawal is documented in STEP and SURMOUNT extension work.

• Sooner visit: pregnancy possible, new steroids, rapid regain, or no loss after months on a full tolerated dose.
• Bring: injection dates, other medicines, and a few weeks of weights if you already track them.
• Do not self-escalate the dose or combine GLP-1 products.

Maintenance is still treatment

Obesity pharmacotherapy is often long-term. A flat scale at a lower weight can be the intended chronic phase, similar to blood-pressure medicine that no longer "drops the number every week." NIDDK frames these medicines as tools that may need continued use to maintain effect for many patients.

Beema Health's medical weight-loss pages describe provider-reviewed telehealth care. A plateau does not mean a person failed a program, and it does not guarantee that any specific medicine will be prescribed. Related articles cover hunger that never quieted, molecule-specific non-response, diet, exercise, and stopping.

Frequently asked questions

Sources

1. [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
2. [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
3. [3] Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide in SURMOUNT-1 and SURMOUNT-4. Clinical Obesity. 2025.
4. [4] NIDDK. Prescription Medications to Treat Overweight & Obesity.
5. [5] Wegovy (semaglutide) injection Prescribing Information. DailyMed.
6. [6] Zepbound (tirzepatide) injection Prescribing Information. Eli Lilly.